Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - losartan potassium; hydrochlorothiazide - oral tablet - 50mg ; 12.5mg

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

lexon (uk) ltd - losartan potassium; hydrochlorothiazide - oral tablet - 50mg ; 12.5mg

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

necessity supplies ltd - losartan potassium; hydrochlorothiazide - oral tablet - 50mg ; 12.5mg

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - losartan potassium; hydrochlorothiazide - oral tablet - 50mg ; 12.5mg

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

bryant ranch prepack - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - cozaar is indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents, including diuretics. cozaar is indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients. (see precautions, race and clinical pharmacology, pharmacodynamics and clinical effects, reduction in the risk of stroke, race.) cozaar is indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes and a history of hypertension. in this population, cozaar reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease (need for dialysis or renal transplantation) (see clinical pharmacology, pharmacodynamics and clinical effects). cozaar is contraindicated in patients who are hypersensit

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

cst pharma ltd - losartan potassium; hydrochlorothiazide - oral tablet - 50mg ; 12.5mg

Malta - inglise - Medicines Authority

merck sharp & dohme limited hertford road, hoddesdon, hertfordshire en11 9bu, united kingdom - hydrochlorothiazide, losartan potassium - film-coated tablet - hydrochlorothiazide 12.5 mg losartan potassium 50 mg - agents acting on the renin-angiotensin system

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

physicians total care, inc. - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - losartan potassium 25 mg - cozaar is indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents, including diuretics. cozaar is indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients. (see precautions, race and clinical pharmacology, pharmacodynamics and clinical effects, reduction in the risk of stroke, race.) cozaar is indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes and a history of hypertension. in this population, cozaar reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease (need for dialysis or renal transplantation) (see clinical pharmacology, pharmacodynamics and clinical effects). cozaar is contraindicated in patients who are hypersensit

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

b & s healthcare - losartan potassium - film coated tablet - 50 milligram - angiotensin ii antagonists, plain

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - hydrochlorothiazide; losartan potassium - film-coated tablet - 50 mg/12.5 milligram(s) - angiotensin ii antagonists and diuretics; losartan and diuretics